	US 12,473,298 B2
	Amide compounds, preparation method therefor, and use thereof in the medical field
Xin Xu, Shanghai (CN); Jia Chen, Shanghai (CN); Zhen Zhang, Shanghai (CN); Liming Zhang, Shanghai (CN); Qimei Wu, Shanghai (CN); Qingyun Jiang, Shanghai (CN); Fengying Guo, Shanghai (CN); Yuyun Zhang, Shanghai (CN); Hao Yu, Shanghai (CN); Xiaojuan Zhang, Shanghai (CN); Kang Sun, Shanghai (CN); Xiaobo Zhou, Shanghai (CN); Chengxu Zang, Shanghai (CN); Yijin Wang, Shanghai (CN); Xiaoer Xia, Shanghai (CN); Yunfei Li, Shanghai (CN); and Jian Ge, Shanghai (CN)
Assigned to SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD., Shanghai (CN); and ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD., Zhejiang (CN)
Appl. No. 17/442,331
Filed by Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai (CN); and Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang (CN)
PCT Filed Mar. 24, 2020, PCT No. PCT/CN2020/080874 § 371(c)(1), (2) Date Sep. 23, 2021, PCT Pub. No. WO2020/192652, PCT Pub. Date Oct. 1, 2020.
Claims priority of application No. 201910228244.8 (CN), filed on Mar. 25, 2019; and application No. 201910687575.8 (CN), filed on Jul. 29, 2019.
Prior Publication US 2022/0024941 A1, Jan. 27, 2022
Int. Cl. C07D 491/107 (2006.01); A61P 35/00 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 495/10 (2006.01)

CPC C07D 491/107 (2013.01) [A61P 35/00 (2018.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 495/10 (2013.01)]

4 Claims

1. A compound or a tautomer, a mesomer, a racemate, an enantiomer, a diastereoisomer or a mixture thereof, a pharmaceutically acceptable salt, a polymorph, a solvate or an isotope derivative thereof, wherein the compound 1s selected from the group consisting of: